Skip to content
  • Home
  • Contact Us
  • Sitemap
  • Home
  • Contact Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Day: September 3, 2024

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More »

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More »

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More »

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More »

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More »

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More »
Page1 Page2 Page3
RECENT POSTS

DRC Urban Trees Identified as Significant CO2 Sinks

April 5, 2026

The Africa We Build Summit Sets Sights on Mobilising Domestic Capital for Industrial Transformation

March 30, 2026

African Football Chief Motsepe to Respect CAS Ruling on Senegal’s Appeal

March 29, 2026

Republic of Congo Presidential Election Sees Sassou NGuesso Poised for Fifth Consecutive Term

March 15, 2026

Africa’s Role in Global Decision-Making Emphasized at African Union Summit

February 16, 2026

Merck Foundation and African First Ladies Advance Oncology Care with 258 Cancer Care Scholarships Across 34 Countries

February 4, 2026
ADVERTISEMENT
Copyright © 2026 Le Congo Tribune. All Rights Reserved.